ORAMED PHARMACEUTICALS INC.
ORMPNasdaq
$4.03
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +104.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$169.1M
Enterprise Value
$151.0M
P/E
1.6
P/S
84.6
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-5.1%
Dividend Yield
—
Revenue (TTM)
$2.0M
Net Income (TTM)
$110.0M
Free Cash Flow (TTM)
-$8.6M
Gross Margin
—
Operating Margin
-712.4%
Net Margin
—
ROE
—
ROIC
-5.4%
Debt / Equity
—
Net Cash
$18.2M
Return 1Y
+103.9%
Company profile
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its flagship product is the ORMD-0801, an oral ingestible insulin capsule. It is also developing an oral glucagon-like peptide-1 capsule.
- CEO
- Nadav Kidron
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- New York
- Website
- oramed.com
Management & directors
- Hexter JoshuaCOO & CBO
- Gabay AvrahamChief Financial Officer
- Kidron NadavPresident and CEO
- Kidron MiriamChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
ORMP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$0.91↓ -578.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.7M | $2.7M | $2.7M | $1.3M | — | $2.0M |
| Gross profit | — | — | — | — | — | $13,000.00 |
| Operating income | -$11.8M | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M |
| Net income | -$11.5M | -$23.0M | -$36.6M | $5.1M | -$19.1M | $64.0M |
| Diluted EPS | — | — | -$0.94 | $0.14 | -$0.48 | $1.50 |
| Operating cash flow | -$12.4M | -$21.2M | -$27.9M | -$10.3M | -$8.4M | -$9.1M |
| Free cash flow | -$12.5M | -$21.6M | -$28.4M | -$10.5M | -$8.4M | -$9.2M |
| Gross margin | — | — | — | — | — | 0.7% |
| Operating margin | -433.8% | -896.2% | -1502.0% | -1176.8% | — | -754.4% |
| Net margin | -424.8% | -850.5% | -1352.6% | 379.7% | — | 3202.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.0M | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | $13,000.00 | $0.00 | $0.00 | $0.00 | — |
| Operating income | -$3.1M | -$3.1M | -$3.6M | -$4.5M | -$2.5M | -$2.4M | -$5.7M | -$3.7M |
| Net income | $9.2M | -$19.6M | -$10.2M | -$7.6M | $13.3M | $48.4M | $10.0M | $38.3M |
| Diluted EPS | $0.22 | -$0.48 | -$0.26 | -$0.19 | $0.31 | $1.13 | $0.25 | $0.91 |
| Operating cash flow | $2.1M | -$7.1M | -$1.9M | -$3.5M | -$3.5M | -$1.6M | -$466,000.00 | -$2.9M |
| Free cash flow | $2.1M | -$7.1M | -$1.9M | -$3.5M | -$3.5M | -$1.6M | -$468,000.00 | -$2.9M |
| Gross margin | — | — | — | 0.7% | — | — | — | — |
| Operating margin | — | — | — | -225.0% | — | — | — | — |
| Net margin | — | — | — | -382.1% | — | — | — | — |
Company news
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Hexter Joshua· COO & CBO | Option exercise | 50,000 | $3.69 | $184,500.00 | filing |
| 2026-07-01 | Hexter Joshua· COO & CBO | Sale | 137,000 | $4.46 | $611,431.00 | filing |
| 2026-07-01 | Gabay Avraham· Chief Financial Officer | Sale | 73,360 | $4.51 | $330,743.56 | filing |
| 2026-03-30 | Kidron Miriam· Chief Scientific Officer | Tax withholding | 435,084 | $3.31 | $1.4M | filing |
| 2026-03-30 | KIDRON NADAV· President and CEO | Tax withholding | 44,818 | $3.31 | $148,347.58 | filing |
| 2026-03-17 | Hexter Joshua· COO & CBO | Award | 95,889 | $0.00 | $0.00 | filing |
| 2026-03-17 | Kidron Miriam· Chief Scientific Officer | Award | 119,558 | $0.00 | $0.00 | filing |
| 2026-03-17 | KIDRON NADAV· President and CEO | Award | 167,005 | $0.00 | $0.00 | filing |
| 2026-03-17 | Gabay Avraham· Chief Financial Officer | Award | 95,889 | $0.00 | $0.00 | filing |
| 2026-03-12 | KIDRON NADAV· President and CEO | Gift | 100,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | Hexter Joshua· COO & CBO | Option exercise | 19,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | Kidron Miriam· Chief Scientific Officer | Option exercise | 19,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | Gabay Avraham· Chief Financial Officer | Option exercise | 19,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | KIDRON NADAV· President and CEO | Option exercise | 109,000 | $0.00 | $0.00 | filing |
| 2026-01-14 | Kidron Miriam· Chief Scientific Officer | Gift | 86,166 | $0.00 | $0.00 | filing |
| 2025-12-31 | Gabay Avraham· Chief Financial Officer | Award | 115,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | KIDRON NADAV· President and CEO | Award | 232,640 | $0.00 | $0.00 | filing |
| 2025-12-31 | KIDRON NADAV· President and CEO | Award | 327,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | Kidron Miriam· Chief Scientific Officer | Award | 121,331 | $0.00 | $0.00 | filing |
| 2025-12-31 | Kidron Miriam· Chief Scientific Officer | Award | 115,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | Hexter Joshua· COO & CBO | Award | 97,328 | $0.00 | $0.00 | filing |
| 2025-12-31 | Hexter Joshua· COO & CBO | Award | 115,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | Gabay Avraham· Chief Financial Officer | Award | 81,216 | $0.00 | $0.00 | filing |
| 2025-12-31 | Shapiro Benjamin | Award | 30,000 | — | — | filing |
| 2025-12-31 | Reznick Yehuda | Award | 6,250 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.